Slattery J M
Department of Clinical Neurosciences, University of Edinburgh.
BMJ. 1994 Apr 2;308(6933):908-10. doi: 10.1136/bmj.308.6933.908.
Vitamin K is given to many babies born in the United Kingdom, but we still do not know if it has substantial hazards. Because the population exposed to vitamin K is very large even quite small hazards would involve many adverse events. It is therefore important to be able to put reasonably close bounds on the potential damage that vitamin K prophylaxis could cause. Past research has not allowed us to do this but a large randomised controlled clinical trial of vitamin K against no vitamin K, enrolling only infants at low risk of haemorrhagic disease, would do so. There is no question that vitamin K is a useful treatment in babies at highest risk of haemorrhagic disease: the question is whether the trend towards use of vitamin K in lower risk babies should be encouraged.
英国许多新生儿都被注射了维生素K，但我们仍不清楚它是否存在重大危害。由于接触维生素K的人群非常庞大，即便危害很小，也会涉及众多不良事件。因此，能够合理地准确界定维生素K预防性用药可能造成的潜在损害非常重要。过去的研究未能让我们做到这一点，但针对低出血性疾病风险婴儿开展的一项维生素K与不使用维生素K的大型随机对照临床试验将会做到。毫无疑问，维生素K对于出血性疾病风险最高的婴儿是一种有效的治疗方法：问题在于，是否应鼓励在低风险婴儿中使用维生素K的趋势。
